ALK and lung cancer: Many types of targeted therapies for lung cancer are currently available, such as epidermal growth factor receptor (EFGR) inhibitors (erlotinib and gefitinib) or anaplastic lymphoma kinase (ALK) inhibitors (crizotinib and alectinib).